– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million […]
Company news
London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, today announces the publication of two papers in key scientific […]
11 March 2021
London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening lung infections, is pleased to announce that the company was […]
26 October 2020
London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that company scientists gave 4 […]
02 March 2020
London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published […]
13 August 2019
Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration […]
02 July 2019
We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting […]
26 April 2019
Pulmocide is pleased to announce another PC945 publication in Antimicrobial Agents and Chemotherapy. The publication is available to download from the link below: AAC.ASM.ORG or the PDF can be downloaded […]
03 July 2017
Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled […]
20 March 2017